Resistance to Activated Protein C, Factor V Leiden and the Prothrombin G20210A Variant in Patients with Colorectal Cancer
Objective: The aim of our study was to determine the frequency of resistance to activated protein C (APC), factor V Leiden (FVL) and the prothrombin G20210A variant in patients with colorectal cancer. Methods: 74 patients with colorectal cancer and 192 colonoscopically selected controls were prospec...
Gespeichert in:
| Veröffentlicht in: | Pathophysiology of haemostasis and thrombosis 2002-01, Vol.32 (1), p.2-7 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7 |
|---|---|
| container_issue | 1 |
| container_start_page | 2 |
| container_title | Pathophysiology of haemostasis and thrombosis |
| container_volume | 32 |
| creator | Paspatis, Gregorios A. Sfyridaki, Aikaterini Papanikolaou, Nikolaos Triantafyllou, Kostantinos Livadiotaki, Aikaterini Kapsoritakis, Andreas Lydataki, Niki |
| description | Objective: The aim of our study was to determine the frequency of resistance to activated protein C (APC), factor V Leiden (FVL) and the prothrombin G20210A variant in patients with colorectal cancer. Methods: 74 patients with colorectal cancer and 192 colonoscopically selected controls were prospectively investigated for the presence of APC resistance, FVL and the prothrombin G20210A variant. APC resistance was measured as the ratio of activated partial thromboplastin times with and without APC (APC sensitivity ratio, APC-SR). The FVL and prothrombin G20210A variant were detected by a polymerase-chain-reaction-based technique. Results: FVL was detected in the heterozygous form in 4 of 74 cancer patients (5.4%) and in 7 of 192 controls (3.6%; p > 0.5, odds ratio: 1.51). After excluding patients and controls with FVL, APC-SR was below 2 in 6 of 70 cancer patients (8.5%) and in 1 of 185 controls (0.5%; p < 0.01, odds ratio: 17.25), and the mean value of APC-SR was significantly lower in cancer patients than the respective level of controls (2.8 vs. 3.7, p < 0.001). The G20210A mutation in the prothrombin gene was found in the heterozygous form in 2 of 74 patients with colorectal cancer (2.7%) and in 5 of 192 colonoscopically control subjects (2.6%; p > 0.5, odds ratio: 1.03). Conclusions: These findings suggest that patients with colorectal cancer have a high frequency of resistance to APC but no significant differences in the frequency of the FVL or G20210A mutation of the prothrombin gene compared to colonoscopically selected controls. |
| doi_str_mv | 10.1159/000057282 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_12214157</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72064840</sourcerecordid><originalsourceid>FETCH-LOGICAL-c358t-40fce3226d61987e9ad2b61599b0b65e183a06ac22e4c8540229474de35c3a3a3</originalsourceid><addsrcrecordid>eNpt0MtrGzEQB2ARWppXDzkXiii0UKgbaaR9Hc2SR8EQU5Jcl1ntbK1kvXIkuSX_feXYdS6VDhLSxwzzY-xMiu9SZtW5SCsroIQDdiQ16ElZavFmf1dwyI5DeBAi4Uq9Y4cSQGqZFUfs-ScFGyKOhnh0fGqi_Y2ROj73LpIdef2NX6KJzvN7PiPb0chx7Hhc0AtZeLdsE7sCAVJM-T16i2Pk6WmO0dIYA_9j44LXbnCeTMSB15tu_pS97XEI9H53nrC7y4vb-noyu7n6UU9nE6OyMk606A0pgLzLZVUWVGEHbb4ZpBVtnpEsFYocDQBpU2ZaAFS60B2pzChM-4R92dZdefe0phCbpQ2GhgFHcuvQFCBynfJK8OsWGu9C8NQ3K2-X6J8bKZpNzs0-52Q_7oqu2yV1r3IXbAKfdwCDwaH3aWYbXp0qlAaZJfdh6x7R_yK_B__afPrv7_z69gU0q65XfwGStJdO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72064840</pqid></control><display><type>article</type><title>Resistance to Activated Protein C, Factor V Leiden and the Prothrombin G20210A Variant in Patients with Colorectal Cancer</title><source>MEDLINE</source><source>Karger Journals Complete</source><source>Alma/SFX Local Collection</source><creator>Paspatis, Gregorios A. ; Sfyridaki, Aikaterini ; Papanikolaou, Nikolaos ; Triantafyllou, Kostantinos ; Livadiotaki, Aikaterini ; Kapsoritakis, Andreas ; Lydataki, Niki</creator><creatorcontrib>Paspatis, Gregorios A. ; Sfyridaki, Aikaterini ; Papanikolaou, Nikolaos ; Triantafyllou, Kostantinos ; Livadiotaki, Aikaterini ; Kapsoritakis, Andreas ; Lydataki, Niki</creatorcontrib><description>Objective: The aim of our study was to determine the frequency of resistance to activated protein C (APC), factor V Leiden (FVL) and the prothrombin G20210A variant in patients with colorectal cancer. Methods: 74 patients with colorectal cancer and 192 colonoscopically selected controls were prospectively investigated for the presence of APC resistance, FVL and the prothrombin G20210A variant. APC resistance was measured as the ratio of activated partial thromboplastin times with and without APC (APC sensitivity ratio, APC-SR). The FVL and prothrombin G20210A variant were detected by a polymerase-chain-reaction-based technique. Results: FVL was detected in the heterozygous form in 4 of 74 cancer patients (5.4%) and in 7 of 192 controls (3.6%; p > 0.5, odds ratio: 1.51). After excluding patients and controls with FVL, APC-SR was below 2 in 6 of 70 cancer patients (8.5%) and in 1 of 185 controls (0.5%; p < 0.01, odds ratio: 17.25), and the mean value of APC-SR was significantly lower in cancer patients than the respective level of controls (2.8 vs. 3.7, p < 0.001). The G20210A mutation in the prothrombin gene was found in the heterozygous form in 2 of 74 patients with colorectal cancer (2.7%) and in 5 of 192 colonoscopically control subjects (2.6%; p > 0.5, odds ratio: 1.03). Conclusions: These findings suggest that patients with colorectal cancer have a high frequency of resistance to APC but no significant differences in the frequency of the FVL or G20210A mutation of the prothrombin gene compared to colonoscopically selected controls.</description><identifier>ISSN: 1424-8832</identifier><identifier>EISSN: 1424-8840</identifier><identifier>DOI: 10.1159/000057282</identifier><identifier>PMID: 12214157</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Activated Protein C Resistance - blood ; Activated Protein C Resistance - epidemiology ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Biomarkers - blood ; Case-Control Studies ; Colorectal Neoplasms - blood ; Colorectal Neoplasms - epidemiology ; Colorectal Neoplasms - genetics ; Comorbidity ; Factor V - genetics ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Hematologic and hematopoietic diseases ; Hemostasis - genetics ; Heterozygote ; Humans ; Male ; Medical sciences ; Middle Aged ; Odds Ratio ; Original Paper ; Other diseases. Semiology ; Partial Thromboplastin Time ; Platelet diseases and coagulopathies ; Point Mutation ; Polymerase Chain Reaction ; Prospective Studies ; Prothrombin - genetics ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><ispartof>Pathophysiology of haemostasis and thrombosis, 2002-01, Vol.32 (1), p.2-7</ispartof><rights>2002 S. Karger AG, Basel</rights><rights>2002 INIST-CNRS</rights><rights>Copyright 2002 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c358t-40fce3226d61987e9ad2b61599b0b65e183a06ac22e4c8540229474de35c3a3a3</citedby><cites>FETCH-LOGICAL-c358t-40fce3226d61987e9ad2b61599b0b65e183a06ac22e4c8540229474de35c3a3a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13734215$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12214157$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Paspatis, Gregorios A.</creatorcontrib><creatorcontrib>Sfyridaki, Aikaterini</creatorcontrib><creatorcontrib>Papanikolaou, Nikolaos</creatorcontrib><creatorcontrib>Triantafyllou, Kostantinos</creatorcontrib><creatorcontrib>Livadiotaki, Aikaterini</creatorcontrib><creatorcontrib>Kapsoritakis, Andreas</creatorcontrib><creatorcontrib>Lydataki, Niki</creatorcontrib><title>Resistance to Activated Protein C, Factor V Leiden and the Prothrombin G20210A Variant in Patients with Colorectal Cancer</title><title>Pathophysiology of haemostasis and thrombosis</title><addtitle>Pathophysiol Haemos Thromb</addtitle><description>Objective: The aim of our study was to determine the frequency of resistance to activated protein C (APC), factor V Leiden (FVL) and the prothrombin G20210A variant in patients with colorectal cancer. Methods: 74 patients with colorectal cancer and 192 colonoscopically selected controls were prospectively investigated for the presence of APC resistance, FVL and the prothrombin G20210A variant. APC resistance was measured as the ratio of activated partial thromboplastin times with and without APC (APC sensitivity ratio, APC-SR). The FVL and prothrombin G20210A variant were detected by a polymerase-chain-reaction-based technique. Results: FVL was detected in the heterozygous form in 4 of 74 cancer patients (5.4%) and in 7 of 192 controls (3.6%; p > 0.5, odds ratio: 1.51). After excluding patients and controls with FVL, APC-SR was below 2 in 6 of 70 cancer patients (8.5%) and in 1 of 185 controls (0.5%; p < 0.01, odds ratio: 17.25), and the mean value of APC-SR was significantly lower in cancer patients than the respective level of controls (2.8 vs. 3.7, p < 0.001). The G20210A mutation in the prothrombin gene was found in the heterozygous form in 2 of 74 patients with colorectal cancer (2.7%) and in 5 of 192 colonoscopically control subjects (2.6%; p > 0.5, odds ratio: 1.03). Conclusions: These findings suggest that patients with colorectal cancer have a high frequency of resistance to APC but no significant differences in the frequency of the FVL or G20210A mutation of the prothrombin gene compared to colonoscopically selected controls.</description><subject>Activated Protein C Resistance - blood</subject><subject>Activated Protein C Resistance - epidemiology</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Case-Control Studies</subject><subject>Colorectal Neoplasms - blood</subject><subject>Colorectal Neoplasms - epidemiology</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Comorbidity</subject><subject>Factor V - genetics</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hemostasis - genetics</subject><subject>Heterozygote</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Odds Ratio</subject><subject>Original Paper</subject><subject>Other diseases. Semiology</subject><subject>Partial Thromboplastin Time</subject><subject>Platelet diseases and coagulopathies</subject><subject>Point Mutation</subject><subject>Polymerase Chain Reaction</subject><subject>Prospective Studies</subject><subject>Prothrombin - genetics</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><issn>1424-8832</issn><issn>1424-8840</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0MtrGzEQB2ARWppXDzkXiii0UKgbaaR9Hc2SR8EQU5Jcl1ntbK1kvXIkuSX_feXYdS6VDhLSxwzzY-xMiu9SZtW5SCsroIQDdiQ16ElZavFmf1dwyI5DeBAi4Uq9Y4cSQGqZFUfs-ScFGyKOhnh0fGqi_Y2ROj73LpIdef2NX6KJzvN7PiPb0chx7Hhc0AtZeLdsE7sCAVJM-T16i2Pk6WmO0dIYA_9j44LXbnCeTMSB15tu_pS97XEI9H53nrC7y4vb-noyu7n6UU9nE6OyMk606A0pgLzLZVUWVGEHbb4ZpBVtnpEsFYocDQBpU2ZaAFS60B2pzChM-4R92dZdefe0phCbpQ2GhgFHcuvQFCBynfJK8OsWGu9C8NQ3K2-X6J8bKZpNzs0-52Q_7oqu2yV1r3IXbAKfdwCDwaH3aWYbXp0qlAaZJfdh6x7R_yK_B__afPrv7_z69gU0q65XfwGStJdO</recordid><startdate>200201</startdate><enddate>200201</enddate><creator>Paspatis, Gregorios A.</creator><creator>Sfyridaki, Aikaterini</creator><creator>Papanikolaou, Nikolaos</creator><creator>Triantafyllou, Kostantinos</creator><creator>Livadiotaki, Aikaterini</creator><creator>Kapsoritakis, Andreas</creator><creator>Lydataki, Niki</creator><general>Karger</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200201</creationdate><title>Resistance to Activated Protein C, Factor V Leiden and the Prothrombin G20210A Variant in Patients with Colorectal Cancer</title><author>Paspatis, Gregorios A. ; Sfyridaki, Aikaterini ; Papanikolaou, Nikolaos ; Triantafyllou, Kostantinos ; Livadiotaki, Aikaterini ; Kapsoritakis, Andreas ; Lydataki, Niki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c358t-40fce3226d61987e9ad2b61599b0b65e183a06ac22e4c8540229474de35c3a3a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Activated Protein C Resistance - blood</topic><topic>Activated Protein C Resistance - epidemiology</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Case-Control Studies</topic><topic>Colorectal Neoplasms - blood</topic><topic>Colorectal Neoplasms - epidemiology</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Comorbidity</topic><topic>Factor V - genetics</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hemostasis - genetics</topic><topic>Heterozygote</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Odds Ratio</topic><topic>Original Paper</topic><topic>Other diseases. Semiology</topic><topic>Partial Thromboplastin Time</topic><topic>Platelet diseases and coagulopathies</topic><topic>Point Mutation</topic><topic>Polymerase Chain Reaction</topic><topic>Prospective Studies</topic><topic>Prothrombin - genetics</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paspatis, Gregorios A.</creatorcontrib><creatorcontrib>Sfyridaki, Aikaterini</creatorcontrib><creatorcontrib>Papanikolaou, Nikolaos</creatorcontrib><creatorcontrib>Triantafyllou, Kostantinos</creatorcontrib><creatorcontrib>Livadiotaki, Aikaterini</creatorcontrib><creatorcontrib>Kapsoritakis, Andreas</creatorcontrib><creatorcontrib>Lydataki, Niki</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pathophysiology of haemostasis and thrombosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paspatis, Gregorios A.</au><au>Sfyridaki, Aikaterini</au><au>Papanikolaou, Nikolaos</au><au>Triantafyllou, Kostantinos</au><au>Livadiotaki, Aikaterini</au><au>Kapsoritakis, Andreas</au><au>Lydataki, Niki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Resistance to Activated Protein C, Factor V Leiden and the Prothrombin G20210A Variant in Patients with Colorectal Cancer</atitle><jtitle>Pathophysiology of haemostasis and thrombosis</jtitle><addtitle>Pathophysiol Haemos Thromb</addtitle><date>2002-01</date><risdate>2002</risdate><volume>32</volume><issue>1</issue><spage>2</spage><epage>7</epage><pages>2-7</pages><issn>1424-8832</issn><eissn>1424-8840</eissn><abstract>Objective: The aim of our study was to determine the frequency of resistance to activated protein C (APC), factor V Leiden (FVL) and the prothrombin G20210A variant in patients with colorectal cancer. Methods: 74 patients with colorectal cancer and 192 colonoscopically selected controls were prospectively investigated for the presence of APC resistance, FVL and the prothrombin G20210A variant. APC resistance was measured as the ratio of activated partial thromboplastin times with and without APC (APC sensitivity ratio, APC-SR). The FVL and prothrombin G20210A variant were detected by a polymerase-chain-reaction-based technique. Results: FVL was detected in the heterozygous form in 4 of 74 cancer patients (5.4%) and in 7 of 192 controls (3.6%; p > 0.5, odds ratio: 1.51). After excluding patients and controls with FVL, APC-SR was below 2 in 6 of 70 cancer patients (8.5%) and in 1 of 185 controls (0.5%; p < 0.01, odds ratio: 17.25), and the mean value of APC-SR was significantly lower in cancer patients than the respective level of controls (2.8 vs. 3.7, p < 0.001). The G20210A mutation in the prothrombin gene was found in the heterozygous form in 2 of 74 patients with colorectal cancer (2.7%) and in 5 of 192 colonoscopically control subjects (2.6%; p > 0.5, odds ratio: 1.03). Conclusions: These findings suggest that patients with colorectal cancer have a high frequency of resistance to APC but no significant differences in the frequency of the FVL or G20210A mutation of the prothrombin gene compared to colonoscopically selected controls.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>12214157</pmid><doi>10.1159/000057282</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1424-8832 |
| ispartof | Pathophysiology of haemostasis and thrombosis, 2002-01, Vol.32 (1), p.2-7 |
| issn | 1424-8832 1424-8840 |
| language | eng |
| recordid | cdi_pubmed_primary_12214157 |
| source | MEDLINE; Karger Journals Complete; Alma/SFX Local Collection |
| subjects | Activated Protein C Resistance - blood Activated Protein C Resistance - epidemiology Aged Aged, 80 and over Biological and medical sciences Biomarkers - blood Case-Control Studies Colorectal Neoplasms - blood Colorectal Neoplasms - epidemiology Colorectal Neoplasms - genetics Comorbidity Factor V - genetics Female Gastroenterology. Liver. Pancreas. Abdomen Hematologic and hematopoietic diseases Hemostasis - genetics Heterozygote Humans Male Medical sciences Middle Aged Odds Ratio Original Paper Other diseases. Semiology Partial Thromboplastin Time Platelet diseases and coagulopathies Point Mutation Polymerase Chain Reaction Prospective Studies Prothrombin - genetics Stomach. Duodenum. Small intestine. Colon. Rectum. Anus |
| title | Resistance to Activated Protein C, Factor V Leiden and the Prothrombin G20210A Variant in Patients with Colorectal Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T23%3A31%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Resistance%20to%20Activated%20Protein%20C,%20Factor%20V%20Leiden%20and%20the%20Prothrombin%20G20210A%20Variant%20in%20Patients%20with%20Colorectal%20Cancer&rft.jtitle=Pathophysiology%20of%20haemostasis%20and%20thrombosis&rft.au=Paspatis,%20Gregorios%20A.&rft.date=2002-01&rft.volume=32&rft.issue=1&rft.spage=2&rft.epage=7&rft.pages=2-7&rft.issn=1424-8832&rft.eissn=1424-8840&rft_id=info:doi/10.1159/000057282&rft_dat=%3Cproquest_pubme%3E72064840%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72064840&rft_id=info:pmid/12214157&rfr_iscdi=true |